肝动脉灌注闪烁显像作为肿瘤微血管定量生物标志物的精确性
本研究在置入肝动脉灌注泵导管的原发或继发性肝癌患者中,经肝动脉灌注泵分别注入37和185 MBq的99mTc-大颗粒聚合白蛋白后行肝脏SPECT,评估肿瘤微血管MAA摄取定量指标的重复性。结果显示重复测量变异小,总肝肿瘤微血管MAA累积量(注射剂量百分比)重复性最好,重复性系数1.6%,肿瘤MAA摄取值为注射剂量的5%至18%。作者认为结果支持将肝动脉灌注SPECT作为血管趋向性肿瘤治疗的放射学反应生物标志物进行临床测试。
要点
- 肝动脉灌注泵SPECT定量肿瘤微血管MAA摄取具有高度重复性,总累积量重复性系数1.6%。
- 肿瘤MAA摄取值为注射剂量的5%至18%,重复测量变异相对于不同肿瘤间观察范围较小。
- 总肝肿瘤微血管MAA累积量的重复测试商数中位数1.10(SD 0.09),范围1.03-1.32,95%CI 1.07-1.19。
核心结论
- 肝动脉灌注SPECT作为肿瘤微血管定量生物标志物在重复性条件下精确性良好,结果支持将其作为血管趋向性肿瘤治疗的放射学反应生物标志物进行临床测试。
研究设计与样本
- 临床研究,原发或继发性肝癌并置入肝动脉灌注泵导管行肝动脉灌注化疗的患者,经肝动脉灌注泵分别行动脉灌注37和185 MBq的99mTc-MAA后行肝脏SPECT,从配对的重复测试SPECT数据集获取肝脏肿瘤MAA摄取定量指标。
关键影像表现/征象
- 肝脏肿瘤MAA摄取定量指标在重复测试肝动脉灌注泵SPECT中高度可重复。
- 重复测量变异相对于不同肿瘤间观察到的测量范围较小。
- 肿瘤MAA摄取值为注射剂量的5%至18%。
诊断标准与关键数值
- 重复性以配对测量值的商数及95%CI和重复性系数(CR)定义。
- 总肝肿瘤微血管MAA累积量(注射剂量百分比)重复性最好,重复测试值商数中位数1.10±0.09(SD),范围1.03-1.32,95%CI 1.07-1.19,CR 1.6%。
临床应用与阅片要点
- 原文结论认为结果支持将肝动脉灌注SPECT作为血管趋向性肿瘤治疗的放射学反应生物标志物进行临床测试。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Optimal clinical development of new cancer therapies targeting tumor vasculature requires new target-specific response assays. This clinical study examined the test-retest repeatability of SPECT as an in vivo assay of angiogenic hepatic tumor microvasculature using an intraarterial infusion of 99mTc-macroaggregated albumin (MAA) delivered via a hepatic artery infusion (HAI) pump.
MATERIALS AND METHODS: Patients with primary or secondary cancerous liver tumors with HAI pump-catheter implants placed for HAI chemotherapy underwent hepatic SPECT after separate arterial infusions of 37 and 185 MBq of 99mTc-MAA via an HAI pump. Quantitative measures of hepatic tumor MAA uptake were obtained from paired test-retest SPECT datasets. Repeatability was defined by quotients of paired measurands with 95% CIs and coefficients of repeatability (CRs).
RESULTS: Test-retest HAI pump SPECT yielded highly repeatable measurements in quantitative indexes of tumor microvasculature. Variability in repeat test-retest measurements was small relative to the range of observed measurements between different tumors. The total hepatic tumor microvascular MAA accumulation (percentage injected dose) proved most repeatable, with test-retest value quotients near unity (quotients: median, 1.10 ± 0.09 [SD]; range, 1.03-1.32; 95% CI, 1.07-1.19) and 1.6% CR. Tumor MAA uptake values ranged from 5% to 18% injected dose.
CONCLUSION: This article describes the precision of HAI SPECT as a quantitative biomarker of tumor microvasculature under conditions of repeatability. The results support clinical testing of HAI SPECT as a radiologic response biomarker for angiotropic tumor therapy.
引用
- Dunphy M, Pandit-Taskar N, Fox JJ, et al. The Precision of Hepatic Arterial Infusion Scintigraphy as a Quantitative Biomarker of Tumor Microvasculature. AJR Am J Roentgenol. 2017. PMID: 28537788. doi:10.2214/AJR.16.17560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。